For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
5
views
127
references
 Top references
cited by
8
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      505
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nontuberculous mycobacterial pulmonary disease (NTM-PD) remains a challenging condition to diagnose and treat effectively. Treatment of NTM-PD is prolonged, frequently associated with adverse effects and has variable success. In this review, we consider the factors influencing clinicians when treating NTM-PD and discuss outcomes from key studies on the pharmacological management of Mycobacterium avium complex pulmonary disease and M. abscessus pulmonary disease. We highlight issues relating to treatment-related toxicity and provide an overview of repurposed and emerging therapies for NTM-PD.

          Abstract

          Despite advances in treatment regimens for nontuberculous mycobacterial pulmonary disease, significant challenges remain. Repurposed and emerging therapies may hold promise. https://bit.ly/3IBPh9q

          Related collections

          Most cited references127

          • Record: found
          • Abstract: not found
          • Article: not found

          An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

          David Griffith, Timothy R Aksamit, Barbara Brown-Elliott … (2007)
          Article 0 comments Cited 701 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus

            Rebekah M. Dedrick, Carlos Guerrero-Bustamante, Rebecca Garlena … (2019)
            A 15-year-old cystic fibrosis patient with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation. Effective lytic phage derivatives that efficiently kill the infectious M. abscessus strain were developed by genome engineering and forward genetics. Intravenous phage treatment was well tolerated and associated with objective clinical improvement including sternal wound closure, improved liver function, and substantial resolution of infected skin nodules.
            Article 0 comments Cited 391 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

              Charles Daley, Jonathan M Iaccarino, Christoph Lange … (2020)
              Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii , and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
              Article 0 comments Cited 217 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Eur Respir Rev
                Journal ID (iso-abbrev): Eur Respir Rev
                Journal ID (publisher-id): ERR
                Journal ID (hwp): errev
                Title: European Respiratory Review
                Publisher: European Respiratory Society
                ISSN (Print): 0905-9180
                ISSN (Electronic): 1600-0617
                Publication date Collection: 31 March 2022
                Publication date (Electronic): 09 February 2022
                Volume: 31
                Issue: 163
                Electronic Location Identifier: 210212
                Affiliations
                [1 ]National Heart and Lung Institute, Imperial College London, London, UK
                [2 ]Host Defence Unit, Dept of Respiratory Medicine, Royal Brompton Hospital, Guy's and St Thomas’ NHS Foundation Trust, London, UK
                [3 ]Division of Mycobacterial and Respiratory Infections, Dept of Medicine, National Jewish Health, Denver, CO, USA
                [4 ]School of Medicine, University of Colorado, Aurora, CO, USA
                Author notes
                Corresponding author: Michael R. Loebinger ( m.loebinger@ 123456rbht.nhs.uk )
                Author information
                https://orcid.org/0000-0002-3142-5795
                Article
                Publisher ID: ERR-0212-2021
                DOI: 10.1183/16000617.0212-2021
                PMC ID: 9488909
                PubMed ID: 35140106
                SO-VID: 5f3a770c-704e-4da5-9ae2-b3fb17095ddd
                Copyright © Copyright ©The authors 2022
                License:

                This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

                History
                Date received : 21 September 2021
                Date accepted : 03 December 2021
                Categories
                Subject: Reviews
                Subject: 4

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content505

                See all similar

                Cited by7

                See all cited by

                Most referenced authors1,942

                See all reference authors